Module 2 - Managing Adverse Events in the Second-Line Setting

This module explores second-line therapies for relapsed or refractory small cell lung cancer (SCLC), reviewing chemotherapy, immunotherapy, and emerging treatments. Key topics include treatment resistance, patient selection, and clinical decision-making through case discussions.
Julia Rotow, MD

Clinical Director, Lowe Center for Thoracic Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Harvard Medical School

Dr. Julia K. Rotow is a thoracic medical oncologist at Dana-Farber Cancer Institute and the Clinical Director of the Lowe Center for Thoracic Oncology. She is also an Assistant Professor of Medicine at Harvard Medical School.

Dr. Rotow completed her medical degree at the David Geffen School of Medicine at UCLA, followed by an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at the University of California, San Francisco.

Her clinical and research interests focus on developing targeted therapies and immunotherapies for oncogene-driven lung cancers, with a particular emphasis on addressing central nervous system metastases.

Beyond her clinical work, Dr. Rotow is an active researcher in the field of lung cancer treatment and is dedicated to advancing care for patients with advanced-stage disease. She is affiliated with both Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she continues to contribute to patient care and research.

1.
IMPLEMENT strategies to manage adverse events (AEs) associated with second-line therapies